Skip to content
Screener

EyePoint, Inc. EYPT Common Stock

Common Stock at other companies

Merck & Co. logo
Merck & Co.MRK
6.5B0.0%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$22K+37.5%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$6K+20.0%
Regenxbio logo
RegenxbioRGNX
$5K0.0%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$5K0.0%
KLR
Kalaris TherapeuticsKLRS
$2K0.0%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.2B+69.1%
Enterprise value$1.11B+67.9%
P/S429.4×+416×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemJune 30, 2026December 31, 2025
Contingencies (Note 12)
Stockholders' equity:
Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $.001 par value, 300,000,000 shares authorized at June 30, 2026 and December 31, 2025; 84,981,843 and 82,826,416 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively8583
Additional paid-in capital1,449,8131,410,047
Accumulated deficit(1,284,280)(1,104,978)
Accumulated other comprehensive income (loss)793961
Total stockholders' equity166,411306,113

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s common stock?
EyePoint, Inc. (EYPT) reported common stock of $85K in Q2 2026.
How has EyePoint, Inc.'s common stock changed year-over-year?
EyePoint, Inc.'s common stock increased by 23.2% year-over-year, from $69K to $85K.
What is the long-term trend for EyePoint, Inc.'s common stock?
Over 5 years (2020 to 2025), EyePoint, Inc.'s common stock has grown at a 35.8% compound annual growth rate (CAGR), from $18K to $83K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about EyePoint, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude